Antidepressant treatment of cytokine-induced mood disorders

Acta Neuropsychiatrica

Volumn 14, Issue 6, 2002, Pages 336-343

  Raison, Charles L ^a   Marcin, Michael ^a   Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Cytokines; Immune; Mood disorders

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; CYTOKINE; MONOAMINE; NEUROTRANSMITTER; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ANOREXIA; ANXIETY; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CYTOKINE PRODUCTION; FATIGUE; HEPATITIS C; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MAJOR DEPRESSION; MOOD DISORDER; NEUROENDOCRINE SYSTEM; NEUROPSYCHIATRY; NONHUMAN; PAIN; REVIEW; SECOND MESSENGER; SYMPTOM;

EID: 0036908624     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-5215.2002.140607.x     Document Type: Review

References (64)

1. Quan N, Stern E L, Whiteside MB, Herkenham M. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol 1999;93:72-80.
2. Watkins LR, Goehler LE, Relton JK et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995;183:27-31.
3. Maier SF, Watkins LR. Cytokines for psychologists, implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83-107.
4. Yirmiya R, Pollak Y, Barak O et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001;24:531-544.
5. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
6. Yirmiya R, Weidenfeld J, Pollak Y et al. Cytokines, 'depression due to a general medical condition', and antidepressant drugs. Adv Exp Med Biol 1999;461:283-316.
7. Greden JF. The burden of recurrent depression: Causes, consequences, and future prospects. J Clin Psychiatry 2001;62 (Suppl. 22):5-9.
8. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993;270:1819-1825.
9. von Ammon Cavanaugh S, Furlanetto LM, Creech SD, Powell LH. Medical illness, past depression, and present depression: A predictive triad for in-hospital mortality. Am J Psychiatry 2001;158:43-48.
10. Koenig HG, George LK, Larson DB, McCullough ME, Branch PS, Kuchibhatla M. Depressive symptoms and nine-year survival of 1,001 male veterans hospitalized with medical illness. Am J Geriatr Psychiatry 1999;7:124131.
11. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24-28.
12. Dantzer R. Cytokine-induced sickness behavior: Where do we stand? Brain Behav Immun 2001;15:7-24.
13. Bluthe RM, Crestani F, Kelley KW, Dantzer R. Mechanisms of the behavioral effects of interleukin 1. Role of prostaglandins and CRF. Ann NY Acad Sci 1992;650:268-275.
14. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001;63:376-386.
15. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-652.
16. Maier SF, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 1995;695:279-282.
17. Pugh CR, Nguyen KT, Gonyea JL et al. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res 1999;106:109-118.
18. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987;238:522-524.
19. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: Laboratory and clinical studies. Ciba Found Symp 1993;172:296-308.
20. Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999;461:117-1127.
21. Musselman DL, Debatista C, Nathan KI, Kilts CD, Schatzberg AF, Nemeroff CB. Biology of mood disorders. In: Textbook of Psychopharmacology, 2nd Edn. (eds Schatzberg, AF, Nemeroff, CB). Washington, DC. American Psychiatric Press, 1998: pp. 549-588.
22. Hu B, Hissong BD, Carlin JM. Interleukin-1 enhances indoleamine 2,3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995;15:617-624.
23. Delgado PL, Price LH, Miller HL et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression, relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330.
24. Papanicolaou DA. Euthyroid Sick Syndrome and the role of cytokines. Rev Endocr Metabol Disord 2000;1:43-48.
25. Haggerty JJ, Jr, Prange AJ, Jr. Borderline hypothyroidism and depression. Ann Rev Med 1995;46:37-46.
26. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999;461:107-116.
27. Evans DL, Staab J, Ward H et al. Depression in the medically ill: Management considerations. Depression Anxiety 1996;4:199-208.
28. Evans DL, Staab JP, Petitto JM et al. Depression in the medical setting: Biopsychological interactions and treatment considerations. J Clin Psychiatry 1999;60 (Suppl. 4):40-55.
29. Sutor B, Rummans TA, Jowsey SG et al. Major depression in medically ill patients. Mayo Clin Proc 1998;73:329-337.
30. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994;151:979-986.
31. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
32. Musselman DL. Higher than normal plasma interleukin6 concentrations in cancer patients with depression: Preliminary findings. Am J Psychiatry 2001;158:1252-1257.
33. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993;4:407-416.
34. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression decreased omega 3 fractions in cholesteryl esters and increased C20: 4 Omega 6/C20: 5 Omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996;38:35-46.
35. Irwin M. Immune correlates of depression. Adv Exp Med Biol 1999;461:1-24.
36. Zorilla E, Luborsky L, McKay J, Roesnthal R et al. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 2001;15:199-226.
37. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993;49:11-27.
38. Pariante CM, Miller AH. Glucocorticoid receptors in major depression, relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
39. Castanon N, Bluthe RM, Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 2001;154:50-60.
40. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 1999;65:1773-1786.
41. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.
42. Schramm TM, Lawford BR, MacDonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361.
43. Gleason OC, Yates WR. Five cases of interferon-alphainduced depression treated with antidepressant therapy. Psychosomatics 1999;40:510-512.
44. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. [see comments.] Am J Gastroenterol 1993;88:760-761.
45. Miller AH, Asnis GM, van Praag HM, Norin AJ. Influence of desmethylimipramine on natural killer cell activity. Psychiatry Res 1986;19:9-15.
46. Frank MG, Hendricks SE, Johnson DR, Wieseler JL, Burke WJ. Antidepressants augment natural killer cell activity, in vivo and in vitro. Neuropsychobiology 1999;39:18-24.
47. Maes M, Song C, Lin AH, Bonaccorso S et al. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999;20:370-379.
48. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 1998;97:309-313.
49. Maes M, Meltzer HY, Bosmans E et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309.
50. Landmann R, Schaub B, Link S, Wacker HR. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biol Psychiatry 1997;41:675-681.
51. Pariante CM, Miller AH. Natural killer cell activity in major depression, a prospective study of the in vivo effects of desmethylimipramine treatment. Eur Neuropsychopharmacol 1995;5 (Suppl.):83-88.
52. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med 1998;60:283-289.
53. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. [see comments.] Biol Psychiatry 1994;35:42-47.
54. Ignatowski TA, Spengler RN. Tumor necrosis factor-alpha: Presynaptic sensitivity is modified after antidepressant drug administration. Brain Res 1994;665:293-299.
55. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-459.
56. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997;52:571-581.
57. Holsboer F. The corticosteroid hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
58. Stout SC, Owens MJ, Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Therap 2002;300:1085-1092.
59. Miller AH, Spencer RL, Trestman RL, Kim C, McEwen BS, Stein M. Adrenal steroid receptor activation in vivo and immune function. Am J Physiol 1991;261 (1 Part 1):E126-E131.
60. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. [see comments.] Arch Gen Psychiatry 1997;54:597-606.
61. Chen J, Rasenick MM. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Therapeut 1995;275:509-517.
62. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993;150:5321-5329.
63. Irie K, Fujii E, Ishida H et al. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br J Pharmacol 2001;133:237-242.
64. Benbernou N, Esnault S, Shin HC, Fekkar H, Guenounou M. Differential regulation of IFN-gamma, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 1997;91:361-368.